Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


20.06.2022

2 BJU Int
1 Clin Cancer Res
1 Clin Imaging
9 Eur Urol
1 Int J Cancer
1 Int J Urol
1 J Magn Reson Imaging
1 J Natl Cancer Inst
2 J Nucl Med
2 J Urol
1 Lancet Oncol
3 N Engl J Med
1 Oncol Rep
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. SUSHENTSEV N, Barrett T, Warren AY, Gnanapragasam VJ, et al
    How and when should radiologists report T-staging on MRI in patients with prostate cancer?
    BJU Int. 2022 Jun 13. doi: 10.1111/bju.15824.
    PubMed        

  2. HARVEY M, Ong WL, Chao M, Udovicich C, et al
    Comprehensive review of hydrogel spacers prior to radiation therapy for prostate cancer.
    BJU Int. 2022 Jun 10. doi: 10.1111/bju.15821.
    PubMed         Abstract available


    Clin Cancer Res

  3. SOWALSKY AG, Figueiredo I, Lis RT, Coleman I, et al
    Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer.
    Clin Cancer Res. 2022 Jun 13. pii: 704873. doi: 10.1158/1078-0432.CCR-22-0851.
    PubMed         Abstract available


    Clin Imaging

  4. WANG G, Yu G, Chen J, Yang G, et al
    Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naive men?
    Clin Imaging. 2022;88:80-86.
    PubMed         Abstract available


    Eur Urol

  5. LENFANT L, Barret E, Roupret M, Rozet F, et al
    Transperineal Prostate Biopsy Is the New Black: What Are the Next Targets?
    Eur Urol. 2022;82:3-5.
    PubMed         Abstract available

  6. PADHANI AR, Schoots IG, Giannarini G
    Re: Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.
    Eur Urol. 2022;82:143-144.
    PubMed        

  7. SAMARATUNGA H, Delahunt B, Egevad L
    Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In pr
    Eur Urol. 2022;82:e15-e16.
    PubMed        

  8. LAO Y, Wang Y, Dong Z
    Re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02411.
    PubMed        

  9. CRABB SJ, Griffiths G, Dunkley D, Downs N, et al
    Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02393.
    PubMed         Abstract available

  10. BEYER K, MacLennan S, Van Hemelrijck M
    Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resi
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02388.
    PubMed        

  11. KISHAN AU, Spratt DE
    Reply to Yongfeng Lao, Yanan Wang, and Zhilong Dong's Letter to the Editor re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02410.
    PubMed        

  12. REDDY D, Ahmed HU
    Reply to Francesco Montorsi, Armando Stabile, Elio Mazzone, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focus
    Eur Urol. 2022 Jun 8. pii: S0302-2838(22)02412.
    PubMed        

  13. DE MAN K, Van Laeken N, Schelfhout V, Fendler WP, et al
    (18)F-PSMA-11 Versus (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.
    Eur Urol. 2022 Jun 8. pii: S0302-2838(22)02383.
    PubMed         Abstract available


    Int J Cancer

  14. CSIZMARIK A, Keresztes D, Nagy N, Bracht T, et al
    Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
    Int J Cancer. 2022 Jun 11. doi: 10.1002/ijc.34159.
    PubMed         Abstract available


    Int J Urol

  15. KONISHI T, Washino S, Okochi T, Miyagawa T, et al
    Combination of biparametric magnetic resonance imaging with prostate-specific antigen density to stratify the risk of significant prostate cancer: Initial biopsy and long-term follow-up results.
    Int J Urol. 2022 Jun 13. doi: 10.1111/iju.14948.
    PubMed         Abstract available


    J Magn Reson Imaging

  16. JOHNSON PM, Tong A, Donthireddy A, Melamud K, et al
    Deep Learning Reconstruction Enables Highly Accelerated Biparametric MR Imaging of the Prostate.
    J Magn Reson Imaging. 2021 Dec 7. doi: 10.1002/jmri.28024.
    PubMed         Abstract available


    J Natl Cancer Inst

  17. KEATING NL, Brooks GA, Landrum MB, Liu PH, et al
    The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
    J Natl Cancer Inst. 2022;114:871-877.
    PubMed         Abstract available


    J Nucl Med

  18. SIEBINGA H, Olde Heuvel J, Rijkhorst EJ, Hendrikx JJMA, et al
    The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on (68)Ga-PSMA-11 PET/CT in Primary Prostate Cancer Patients.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264101. doi: 10.2967/jnumed.122.264101.
    PubMed         Abstract available

  19. POMYKALA KL, Herrmann K, Padhani AR, Hofman MS, et al
    Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Prostate Cancer: We have the answers.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264394. doi: 10.2967/jnumed.122.264394.
    PubMed        


    J Urol

  20. FAN S, Zhang Z, Wang J, Xiong S, et al
    Robot-Assisted Radical Prostatectomy Using the KangDuo Surgical Robot-01 System: A Prospective, Single-Center, Single-Arm Clinical Study.
    J Urol. 2022;208:119-127.
    PubMed         Abstract available

  21. TOPS SCM, Grootenhuis JGA, Derksen AM, Giardina F, et al
    The Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy Infectious Complications.
    J Urol. 2022;208:109-118.
    PubMed         Abstract available


    Lancet Oncol

  22. AGARWAL N, McGregor B, Maughan BL, Dorff TB, et al
    Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
    Lancet Oncol. 2022 Jun 8. pii: S1470-2045(22)00278.
    PubMed         Abstract available


    N Engl J Med

  23. TURCO F, Tucci M, Buttigliero C
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed        

  24. BOWLING GC, Dimitrakoff JD
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed        

  25. SMITH MR
    Darolutamide in Metastatic Prostate Cancer. Reply.
    N Engl J Med. 2022;386:2345.
    PubMed        


    Oncol Rep

  26. MENDEZ-CLEMENTE A, Bravo-Cuellar A, Gonzalez-Ochoa S, Santiago-Mercado M, et al
    Dual STAT3 and IL6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL6/IL6R/STAT3 axis.
    Oncol Rep. 2022;48.
    PubMed         Abstract available


    PLoS One

  27. HARKE NN, Wagner C, Hermann RM, Hadaschik BA, et al
    Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment.
    PLoS One. 2022;17:e0269827.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: